Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Jan 1;144(1):29–34.

Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.

D W Molloy 1, G H Guyatt 1, D B Wilson 1, R Duke 1, L Rees 1, J Singer 1
PMCID: PMC1452525  PMID: 1984813

Abstract

OBJECTIVE: To determine the efficacy of tetrahydroaminoacridine (THA) in Alzheimer's disease. DESIGN: Randomized, double-blind, multiple crossover trial with three treatment periods, each consisting of 3 weeks of active drug therapy and 3 weeks of placebo administration. SETTING: Referral-based geriatric practice in a community hospital. PATIENTS: Thirty-four patients with moderate to severe Alzheimer's disease. Subjects were included if they had stage 3 to 6 disease (as determined by the Reisberg scale) and had not been taking psychotropic drugs for at least 1 month and if informed consent had been obtained from the patients and their next of kin. INTERVENTIONS: Fifty to 100 mg of THA daily and matched placebo. RESULTS: Of the initial 34 patients 14 experienced liver toxicity and 3 gastrointestinal side effects during the study; however, all 22 who completed the study were able to tolerate at least the minimum dose. For the 22 patients there was no clinically or statistically significant effect of THA on cognition, functional status or behaviour. The results for individual patients showed no subgroup of THA-responsive patients. CONCLUSION: THA has no clinically important benefits in Alzheimer's disease and is associated with appreciable toxic effects.

Full text

PDF
29

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolfsson R., Gottfries C. G., Roos B. E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry. 1979 Sep;135:216–223. doi: 10.1192/bjp.135.3.216. [DOI] [PubMed] [Google Scholar]
  2. Blessed G., Tomlinson B. E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968 Jul;114(512):797–811. doi: 10.1192/bjp.114.512.797. [DOI] [PubMed] [Google Scholar]
  3. Bowen D. M., Allen S. J., Benton J. S., Goodhardt M. J., Haan E. A., Palmer A. M., Sims N. R., Smith C. C., Spillane J. A., Esiri M. M. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem. 1983 Jul;41(1):266–272. doi: 10.1111/j.1471-4159.1983.tb11838.x. [DOI] [PubMed] [Google Scholar]
  4. Chatellier G., Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. BMJ. 1990 Feb 24;300(6723):495–499. doi: 10.1136/bmj.300.6723.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crow T. J., Grove-White I. G. An analysis of the learning deficit following hyoscine administration to man. Br J Pharmacol. 1973 Oct;49(2):322–327. doi: 10.1111/j.1476-5381.1973.tb08379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies P., Katzman R., Terry R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 1980 Nov 20;288(5788):279–280. doi: 10.1038/288279a0. [DOI] [PubMed] [Google Scholar]
  7. Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
  8. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 1979 Aug 3;171(2):319–327. doi: 10.1016/0006-8993(79)90336-6. [DOI] [PubMed] [Google Scholar]
  9. Flicker C. Neuropsychological evaluation of treatment effects in the elderly: a critique of tests in current use. Psychopharmacol Bull. 1988;24(4):535–556. [PubMed] [Google Scholar]
  10. Gauthier S., Bouchard R., Lamontagne A., Bailey P., Bergman H., Ratner J., Tesfaye Y., Saint-Martin M., Bacher Y., Carrier L. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med. 1990 May 3;322(18):1272–1276. doi: 10.1056/NEJM199005033221804. [DOI] [PubMed] [Google Scholar]
  11. Guyatt G. H., Keller J. L., Jaeschke R., Rosenbloom D., Adachi J. D., Newhouse M. T. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med. 1990 Feb 15;112(4):293–299. doi: 10.7326/0003-4819-112-4-293. [DOI] [PubMed] [Google Scholar]
  12. Guyatt G., Sackett D., Adachi J., Roberts R., Chong J., Rosenbloom D., Keller J. A clinician's guide for conducting randomized trials in individual patients. CMAJ. 1988 Sep 15;139(6):497–503. [PMC free article] [PubMed] [Google Scholar]
  13. Guyatt G., Sackett D., Taylor D. W., Chong J., Roberts R., Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986 Apr 3;314(14):889–892. doi: 10.1056/NEJM198604033141406. [DOI] [PubMed] [Google Scholar]
  14. HARDY T. K., WAKELY D. The amnesic properties of hyoscine and atropine in pre-anaesthetic medication. Anaesthesia. 1962 Jul;17:331–336. doi: 10.1111/j.1365-2044.1962.tb13473.x. [DOI] [PubMed] [Google Scholar]
  15. Hachinski V. C., Iliff L. D., Zilhka E., Du Boulay G. H., McAllister V. L., Marshall J., Russell R. W., Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975 Sep;32(9):632–637. doi: 10.1001/archneur.1975.00490510088009. [DOI] [PubMed] [Google Scholar]
  16. Isaacs B., Akhtar A. J. The set test: a rapid test of mental function in old people. Age Ageing. 1972 Nov;1(4):222–226. doi: 10.1093/ageing/1.4.222. [DOI] [PubMed] [Google Scholar]
  17. KAHN R. L., GOLDFARB A. I., POLLACK M., PECK A. Brief objective measures for the determination of mental status in the aged. Am J Psychiatry. 1960 Oct;117:326–328. doi: 10.1176/ajp.117.4.326. [DOI] [PubMed] [Google Scholar]
  18. Kaye W. H., Sitaram N., Weingartner H., Ebert M. H., Smallberg S., Gillin J. C. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. Biol Psychiatry. 1982 Feb;17(2):275–280. [PubMed] [Google Scholar]
  19. Lawton M. P., Brody E. M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179–186. [PubMed] [Google Scholar]
  20. MAHONEY F. I., BARTHEL D. W. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61–65. [PubMed] [Google Scholar]
  21. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  22. Molloy D. W., Alemayehu E., Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry. 1991 Jan;148(1):102–105. doi: 10.1176/ajp.148.1.102. [DOI] [PubMed] [Google Scholar]
  23. Molloy D. W., Beerschoten D. A., Borrie M. J., Crilly R. G., Cape R. D. Acute effects of exercise on neuropsychological function in elderly subjects. J Am Geriatr Soc. 1988 Jan;36(1):29–33. doi: 10.1111/j.1532-5415.1988.tb03430.x. [DOI] [PubMed] [Google Scholar]
  24. Molloy D. W., Cape R. D. Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiol Aging. 1989 Mar-Apr;10(2):199–204. doi: 10.1016/0197-4580(89)90031-6. [DOI] [PubMed] [Google Scholar]
  25. Niederehe G. TRIMS Behavioral Problem Checklist (BPC). Psychopharmacol Bull. 1988;24(4):771–778. [PubMed] [Google Scholar]
  26. Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. N Engl J Med. 1987 Jun 18;316(25):1603–1605. doi: 10.1056/NEJM198706183162512. [DOI] [PubMed] [Google Scholar]
  27. Perry E. K., Tomlinson B. E., Blessed G., Bergmann K., Gibson P. H., Perry R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978 Nov 25;2(6150):1457–1459. doi: 10.1136/bmj.2.6150.1457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Reisberg B., Ferris S. H., de Leon M. J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982 Sep;139(9):1136–1139. doi: 10.1176/ajp.139.9.1136. [DOI] [PubMed] [Google Scholar]
  29. Rogawski M. A. Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. Eur J Pharmacol. 1987 Oct 6;142(1):169–172. doi: 10.1016/0014-2999(87)90670-4. [DOI] [PubMed] [Google Scholar]
  30. Rogers J. D., Brogan D., Mirra S. S. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol. 1985 Feb;17(2):163–170. doi: 10.1002/ana.410170210. [DOI] [PubMed] [Google Scholar]
  31. Rossor M. N., Garrett N. J., Johnson A. L., Mountjoy C. Q., Roth M., Iversen L. L. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain. 1982 Jun;105(Pt 2):313–330. doi: 10.1093/brain/105.2.313. [DOI] [PubMed] [Google Scholar]
  32. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986 Nov 13;315(20):1241–1245. doi: 10.1056/NEJM198611133152001. [DOI] [PubMed] [Google Scholar]
  33. Summers W. K., Viesselman J. O., Marsh G. M., Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry. 1981 Feb;16(2):145–153. [PubMed] [Google Scholar]
  34. Yates C. M., Allison Y., Simpson J., Maloney A. F., Gordon A. Dopamine in Alzheimer's disease and senile dementia. Lancet. 1979 Oct 20;2(8147):851–852. doi: 10.1016/s0140-6736(79)92202-5. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES